Pharmicell Co., Ltd. (KRX:005690)

Market Cap	1.06T +94.9%
Revenue (ttm)	23.94B -3.6%
Net Income	-26.78B
EPS	-613.75
Shares Out	60.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,556,883
Average Volume	2,140,001
Open	18,120
Previous Close	18,140
Day's Range	17,630 - 18,260
52-Week Range	8,150 - 20,800
Beta	0.51
RSI	63.58
Earnings Date	n/a

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1968
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 005690

Financial Performance

In 2013, Pharmicell's revenue was 33.41 billion, an increase of 200.63% compared to the previous year's 11.11 billion. Losses were -25.70 billion, 45.7% more than in 2012.